GSA Capital Partners LLP Has $873,000 Stake in Flexion Therapeutics Inc (FLXN)

GSA Capital Partners LLP lessened its stake in shares of Flexion Therapeutics Inc (NASDAQ:FLXN) by 41.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 36,100 shares of the specialty pharmaceutical company’s stock after selling 25,400 shares during the period. GSA Capital Partners LLP owned approximately 0.10% of Flexion Therapeutics worth $873,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp lifted its stake in Flexion Therapeutics by 27.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 2,716,189 shares of the specialty pharmaceutical company’s stock valued at $54,921,000 after acquiring an additional 591,981 shares during the period. Capital World Investors lifted its stake in shares of Flexion Therapeutics by 2.0% in the 2nd quarter. Capital World Investors now owns 2,538,000 shares of the specialty pharmaceutical company’s stock valued at $51,318,000 after purchasing an additional 49,000 shares during the period. State Street Corp lifted its stake in shares of Flexion Therapeutics by 66.3% in the 2nd quarter. State Street Corp now owns 1,379,202 shares of the specialty pharmaceutical company’s stock valued at $27,888,000 after purchasing an additional 549,948 shares during the period. Vanguard Group Inc. lifted its stake in shares of Flexion Therapeutics by 5.9% in the 2nd quarter. Vanguard Group Inc. now owns 1,054,464 shares of the specialty pharmaceutical company’s stock valued at $21,321,000 after purchasing an additional 59,143 shares during the period. Finally, Wasatch Advisors Inc. lifted its stake in shares of Flexion Therapeutics by 58.7% in the 2nd quarter. Wasatch Advisors Inc. now owns 1,018,219 shares of the specialty pharmaceutical company’s stock valued at $20,588,000 after purchasing an additional 376,745 shares during the period. 72.78% of the stock is currently owned by institutional investors.

In related news, insider Michael D. Clayman bought 5,000 shares of the firm’s stock in a transaction on Wednesday, November 8th. The shares were bought at an average price of $23.60 per share, with a total value of $118,000.00. Following the completion of the transaction, the insider now directly owns 35,395 shares of the company’s stock, valued at approximately $835,322. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Neil Bodick bought 2,700 shares of the firm’s stock in a transaction on Tuesday, November 21st. The stock was bought at an average cost of $24.49 per share, for a total transaction of $66,123.00. Following the transaction, the insider now directly owns 64,605 shares of the company’s stock, valued at $1,582,176.45. The disclosure for this purchase can be found here. Corporate insiders own 15.98% of the company’s stock.

Shares of Flexion Therapeutics Inc (NASDAQ FLXN) opened at $25.47 on Wednesday. The company has a debt-to-equity ratio of 0.87, a current ratio of 12.93 and a quick ratio of 12.93. Flexion Therapeutics Inc has a 1-year low of $16.51 and a 1-year high of $32.25. The stock has a market cap of $943.40, a PE ratio of -7.26 and a beta of 1.15.

Several equities analysts recently issued reports on FLXN shares. Needham & Company LLC boosted their target price on shares of Flexion Therapeutics from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Monday, October 9th. Wells Fargo & Co set a $39.00 price objective on shares of Flexion Therapeutics and gave the stock a “buy” rating in a research report on Friday, October 6th. Northland Securities restated a “buy” rating and set a $40.00 price objective on shares of Flexion Therapeutics in a research report on Wednesday, October 4th. Royal Bank of Canada set a $44.00 price objective on shares of Flexion Therapeutics and gave the stock a “buy” rating in a research report on Monday, September 11th. Finally, Laidlaw restated a “buy” rating and set a $38.00 price objective (up from $35.00) on shares of Flexion Therapeutics in a research report on Tuesday, October 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. Flexion Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $106.25.

WARNING: This news story was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.com-unik.info/2017/12/27/gsa-capital-partners-llp-has-873000-stake-in-flexion-therapeutics-inc-flxn.html.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

What are top analysts saying about Flexion Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Flexion Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit